MA41311B1 - Peptides antagonistes du cgrp - Google Patents
Peptides antagonistes du cgrpInfo
- Publication number
- MA41311B1 MA41311B1 MA41311A MA41311A MA41311B1 MA 41311 B1 MA41311 B1 MA 41311B1 MA 41311 A MA41311 A MA 41311A MA 41311 A MA41311 A MA 41311A MA 41311 B1 MA41311 B1 MA 41311B1
- Authority
- MA
- Morocco
- Prior art keywords
- cgrp antagonist
- antagonist peptides
- compounds
- formula
- peptides
- Prior art date
Links
- 229940127597 CGRP antagonist Drugs 0.000 title abstract 2
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci : dans laquelle m, p, a, ar1, ar2, ar3, r1, r2 et r3 sont tels que définis dans la description. Les composés de formule (i) peuvent être utilisés comme antagonistes de cgrp et peuvent être utilisés pour traiter
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562100371P | 2015-01-06 | 2015-01-06 | |
| PCT/EP2016/050110 WO2016110499A1 (fr) | 2015-01-06 | 2016-01-06 | Peptides antagonistes du cgrp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41311A MA41311A (fr) | 2017-11-14 |
| MA41311B1 true MA41311B1 (fr) | 2022-10-31 |
Family
ID=55071041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41311A MA41311B1 (fr) | 2015-01-06 | 2016-01-06 | Peptides antagonistes du cgrp |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9969775B2 (fr) |
| EP (1) | EP3242882B1 (fr) |
| JP (1) | JP6929227B2 (fr) |
| KR (1) | KR102713739B1 (fr) |
| CN (1) | CN107207567B (fr) |
| AR (1) | AR103499A1 (fr) |
| AU (1) | AU2016206059B2 (fr) |
| BR (1) | BR112017013413A2 (fr) |
| CL (1) | CL2017001761A1 (fr) |
| CO (1) | CO2017007940A2 (fr) |
| DK (1) | DK3242882T3 (fr) |
| EA (1) | EA032082B1 (fr) |
| ES (1) | ES2924410T3 (fr) |
| HR (1) | HRP20220941T1 (fr) |
| HU (1) | HUE059379T2 (fr) |
| IL (1) | IL252903B (fr) |
| JO (1) | JO3669B1 (fr) |
| LT (1) | LT3242882T (fr) |
| MA (1) | MA41311B1 (fr) |
| MD (1) | MD3242882T2 (fr) |
| MX (1) | MX387920B (fr) |
| MY (1) | MY196439A (fr) |
| PH (1) | PH12017501214A1 (fr) |
| PL (1) | PL3242882T3 (fr) |
| PT (1) | PT3242882T (fr) |
| RS (1) | RS63467B1 (fr) |
| SA (1) | SA517381865B1 (fr) |
| SG (1) | SG11201705306UA (fr) |
| SI (1) | SI3242882T1 (fr) |
| TN (1) | TN2017000248A1 (fr) |
| TW (1) | TWI717331B (fr) |
| UA (1) | UA121490C2 (fr) |
| WO (1) | WO2016110499A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018362018A1 (en) * | 2017-11-06 | 2020-06-25 | Auckland Uniservices Limited | Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof |
| EP4647082A1 (fr) | 2024-05-08 | 2025-11-12 | NUVIE BIO, Inc. | Composition pharmaceutique comprenant un antagoniste du récepteur du cgrp pour le traitement de la migraine aiguë |
| WO2025202938A1 (fr) | 2024-03-26 | 2025-10-02 | Nuvie Bio, Inc. | Composition pharmaceutique comprenant un antagoniste du récepteur cgrp pour le traitement de la migraine aiguë |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268474B1 (en) * | 1998-04-30 | 2001-07-31 | Creighton University | Peptide antagonists of CGRP-receptor superfamily and methods of use |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| WO2006041830A2 (fr) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Antagonistes du recepteur de cgrp |
| AU2006205830A1 (en) * | 2005-01-17 | 2006-07-20 | Jerini Ag | C5a receptor antagonists |
| CA2599925A1 (fr) * | 2005-03-14 | 2006-09-21 | Merck & Co., Inc. | Antagonistes du recepteur du cgrp |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| ES2433251T5 (es) * | 2005-11-14 | 2020-03-13 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos |
| EP2027106A2 (fr) * | 2006-06-13 | 2009-02-25 | Vertex Pharmaceuticals Incorporated | Antagonistes du récepteur du cgrp |
| EP2807187B1 (fr) | 2012-01-26 | 2017-07-26 | Christopher J. Soares | Antagonistes peptidiques de la famille calcitonine cgrp d'hormones peptidiques et leur utilisation |
-
2016
- 2016-01-04 JO JOP/2016/0002A patent/JO3669B1/ar active
- 2016-01-05 TW TW105100158A patent/TWI717331B/zh active
- 2016-01-05 AR ARP160100008A patent/AR103499A1/es active IP Right Grant
- 2016-01-06 EP EP16700059.5A patent/EP3242882B1/fr active Active
- 2016-01-06 HR HRP20220941TT patent/HRP20220941T1/hr unknown
- 2016-01-06 HU HUE16700059A patent/HUE059379T2/hu unknown
- 2016-01-06 RS RS20220739A patent/RS63467B1/sr unknown
- 2016-01-06 ES ES16700059T patent/ES2924410T3/es active Active
- 2016-01-06 MX MX2017008893A patent/MX387920B/es unknown
- 2016-01-06 AU AU2016206059A patent/AU2016206059B2/en active Active
- 2016-01-06 EA EA201791456A patent/EA032082B1/ru not_active IP Right Cessation
- 2016-01-06 PT PT167000595T patent/PT3242882T/pt unknown
- 2016-01-06 KR KR1020177021133A patent/KR102713739B1/ko active Active
- 2016-01-06 DK DK16700059.5T patent/DK3242882T3/da active
- 2016-01-06 JP JP2017553460A patent/JP6929227B2/ja active Active
- 2016-01-06 WO PCT/EP2016/050110 patent/WO2016110499A1/fr not_active Ceased
- 2016-01-06 MY MYPI2017702432A patent/MY196439A/en unknown
- 2016-01-06 TN TN2017000248A patent/TN2017000248A1/en unknown
- 2016-01-06 SG SG11201705306UA patent/SG11201705306UA/en unknown
- 2016-01-06 MA MA41311A patent/MA41311B1/fr unknown
- 2016-01-06 US US15/540,460 patent/US9969775B2/en active Active
- 2016-01-06 LT LTEPPCT/EP2016/050110T patent/LT3242882T/lt unknown
- 2016-01-06 MD MDE20170266T patent/MD3242882T2/ro unknown
- 2016-01-06 SI SI201631576T patent/SI3242882T1/sl unknown
- 2016-01-06 PL PL16700059.5T patent/PL3242882T3/pl unknown
- 2016-01-06 CN CN201680005041.7A patent/CN107207567B/zh active Active
- 2016-01-06 UA UAA201708029A patent/UA121490C2/uk unknown
- 2016-01-06 BR BR112017013413-6A patent/BR112017013413A2/pt active Search and Examination
-
2017
- 2017-06-14 IL IL252903A patent/IL252903B/en active IP Right Grant
- 2017-06-29 PH PH12017501214A patent/PH12017501214A1/en unknown
- 2017-07-03 CL CL2017001761A patent/CL2017001761A1/es unknown
- 2017-07-04 SA SA517381865A patent/SA517381865B1/ar unknown
- 2017-08-04 CO CONC2017/0007940A patent/CO2017007940A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA39172B1 (fr) | Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines | |
| MX381588B (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| EA201991697A1 (ru) | Сульфоксиминовые ингибиторы гликозидазы | |
| DE602004013563D1 (de) | Rantagonisten | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| EA201390683A1 (ru) | Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp | |
| EP3697452A4 (fr) | Vecteurs lentiviraux pour l'administration de pklr pour traiter une déficience en pyruvate kinase | |
| MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA42776B1 (fr) | Composés utiles pour l'inhibition du ror-gamma-t | |
| JO3742B1 (ar) | مركب بيرانو داي بيريدين | |
| MA39305A3 (fr) | Dérivés d'éthynyle | |
| PH12017501214A1 (en) | Cgrp antagonist peptides | |
| MA46965B1 (fr) | Modulateurs de gamma ror (rory) | |
| MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer | |
| TR201908391T4 (tr) | Aminoester türevleri. | |
| MA50899B1 (fr) | Composés utiles pour l'inhibition de cdk7 |